About Revance Therapeutics
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: RVNC
- Previous Close: $20.40
- 50 Day Moving Average: $21.05
- 200 Day Moving Average: $17.43
- 52-Week Range: $12.35 - $24.30
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.98
- P/E Growth: -0.58
- Market Cap: $567.45M
- Outstanding Shares: 28,515,000
- Beta: 1.7
- Net Margins: -28,187.33%
- Return on Equity: -37.31%
- Return on Assets: -33.87%
Companies Related to Revance Therapeutics:
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 11.92%
- Quick Ratio: 11.92%
What is Revance Therapeutics' stock symbol?
Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."
Where is Revance Therapeutics' stock going? Where will Revance Therapeutics' stock price be in 2017?
5 analysts have issued 1-year price targets for Revance Therapeutics' stock. Their predictions range from $22.00 to $55.00. On average, they anticipate Revance Therapeutics' stock price to reach $37.60 in the next twelve months.
When will Revance Therapeutics announce their earnings?
Revance Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
What are analysts saying about Revance Therapeutics stock?
Here are some recent quotes from research analysts about Revance Therapeutics stock:
According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (1/12/2017)
Brean Capital analysts commented, "more clarity on the Phase III trial design for Glabellar lines" before rating the company as a Buy. Taking into consideration RT-001's loss and Glabellar lines' lack of visibility, the analyst claimed there were "no meaningful catalysts in the immediate time horizon." (6/14/2016)
Who owns Revance Therapeutics stock?
Revance Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (11.50%), Arrowpoint Asset Management LLC (7.08%), State Street Corp (1.14%), FMR LLC (0.35%), Vivo Capital LLC (0.27%) and Federated Investors Inc. PA (0.07%). Company insiders that own Revance Therapeutics stock include Arthur Peter Bertolino, Curtis Ruegg and L Daniel Browne.
Who bought Revance Therapeutics stock? Who is buying Revance Therapeutics stock?
Revance Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Arrowpoint Asset Management LLC, Franklin Resources Inc., FMR LLC, State Street Corp and Russell Investments Group Ltd..
How do I buy Revance Therapeutics stock?
Shares of Revance Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Revance Therapeutics stock cost?
One share of Revance Therapeutics stock can currently be purchased for approximately $19.90.